DEVELOPMENT OF TARGETED THERAPIES BASED ON BIOTECHNOLOGICAL PLATFORMS FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA
DOI:
https://doi.org/10.63330/aurumpub.024-001Keywords:
SCCHN, Targeted therapy, Immunotherapy, Biotechnology, Precision medicineAbstract
Squamous cell carcinoma of the head and neck (SCCHN) is one of the most prevalent and high-impact malignant neoplasms worldwide, characterized by elevated morbidity and mortality and significant therapeutic challenges. Traditionally managed through surgery, chemotherapy, and radiotherapy, SCCHN often presents limited responses in advanced stages, reinforcing the need for more specific and effective therapeutic approaches. In this context, the development of targeted therapies based on biotechnological platforms has emerged as one of the most promising strategies in modern oncology. This study, conducted through an integrative literature review, analyzed scientific evidence published between 2015 and 2025 on immunotherapies, signaling pathway inhibitors, gene therapies, and cellular technologies applied to SCCHN. Findings highlight significant advances in immunotherapy, particularly with immune checkpoint inhibitors, which have improved survival outcomes in metastatic and recurrent disease. Additionally, targeted therapies directed at EGFR, kinase inhibitors, and combination regimens have expanded tumor control while reducing toxicities. Emerging platforms, such as CAR-T cells, therapeutic vaccines, and nanobiotechnology, also demonstrate substantial clinical potential, despite persistent challenges related to treatment resistance, cost, and accessibility. It is concluded that the incorporation of predictive biomarkers and precision-based therapeutic strategies represents the new paradigm for SCCHN management, requiring ongoing investment in innovation, professional training, and broader access to emerging technologies.
Downloads
References
Botticelli, Alessio; Cirillo, Angela; Strigari, Lorenzo; Valentini, Federica; Cerbelli, Barbara; Scagnoli, Silvia; Cerbelli, Elisabetta; Zizzari, Ignazio Giovanni; Da Rocca, Chiara; D'Amati, Giuseppe; Polimeni, Aldo; Nuti, Maria; Merlano, Marco Carlo; Mezi, Sergio; Marchetti, Paolo.
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Frontiers in Immunology, v. 12, p. 705096, 2021. Disponível em: https://doi.org/10.3389/fimmu.2021.705096
Caudell, James J.; Gillison, Maura L.; Maghami, Ellie; Spencer, Steven; Pfister, David G.; Adkins, Douglas; Birkeland, Andrew C.; Brizel, David M.; Busse, Patrick M.; Cmelak, Anthony J.; Colevas, Alan David; Eisele, David W.; Galloway, Thomas; Geiger, Jennifer L.; Haddad, Robert I.; Hicks, William L.; Hitchcock, Yuhchyau J.; Jimeno, Antonio; Leizman, Daniel; Mell, Loren K.; Mittal, Baburam B.; Pinto, Herman A.; Rocco, James W.; Rodriguez, Cheryl P.; Savvides, Paul S.; Schwartz, David; Shah, Jatin P.; Sher, David; John, Maie St.; Weber, Randal S.; Weinstein, Gary; Worden, Francis; Yang, Bruce J.; Yom, Sue S.; Zhen, Weining; Burns, Justin L.; Darlow, Stacie D. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. Journal of the National Comprehensive Cancer Network, v. 20, n. 3, p. 224-234, 2022. Disponível em: https://doi.org/10.6004/jnccn.2022.0016
Colevas, Alan David; Cmelak, Anthony J.; Pfister, David G.; Spencer, Steven; Adkins, Douglas; Birkeland, Andrew C.; Brizel, David M.; Busse, Patrick M.; Caudell, James J.; Durm, Gregory; Fakhry, Carole; Galloway, Thomas; Geiger, Jennifer L.; Gillison, Maura L.; Glastonbury, Christine; Haddad, Robert I.; Hicks, William L.; Hitchcock, Yuhchyau J.; Jimeno, Antonio; Juloori, Anurag; Kase, Matthew; Leizman, Daniel; Maghami, Ellie; Mell, Loren K.; Mittal, Baburam B.; Pinto, Herman A.; Price, Kara; Rocco, James W.; Rodriguez, Cheryl P.; Schwartz, David; Shah, Jatin P.; Sher, David; John, Maie St.; Wang, Helen; Weinstein, Gary; Worden, Francis; Bruce, Jonathan Y.; Yom, Sue S.; Zhen, Weining; Montgomery, Sandra; Darlow, Stacie D. NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025. Journal of the National Comprehensive Cancer Network, v. 23, n. 2, p. 2-11, 2025. Disponível em: https://doi.org/10.6004/jnccn.2025.0007
DePeaux, Kristin; Delgoffe, Greg M. Metabolic barriers to cancer immunotherapy. Nature Reviews Immunology, v. 21, n. 12, p. 785-797, 2021. Disponível em: https://doi.org/10.1038/s41577-021-00541-y
Dupont, Marie; de Bernardi, Aline; Vanacker, Hélène; Dufresne, Anne; Brahmi, Mickaël; Blay, Jean-Yves. Cellular therapies in sarcoma and other solid tumors. Current Opinion in Oncology, v. 37, n. 4, p. 365-371, 2025. Disponível em: https://doi.org/10.1097/CCO.0000000000001152
Feng, Bo; Zhao, Dong; Zhang, Zhaoyu; Jia, Rui; Schuler, Patrick J.; Hess, Jochen. Ligand-receptor interactions combined with histopathology for improved prognostic modeling in HPV-negative head and neck squamous cell carcinoma. NPJ Precision Oncology, v. 9, n. 1, p. 57, 2025. Disponível em: https://doi.org/10.1038/s41698-025-00844-6
Han, Jiye; Kioi, Michiko; Chu, Walter S.; Chu, W. S.; et al. Identificação de potenciais alvos terapêuticos no carcinoma de células escamosas de cabeça e pescoço em humanos. Head & Neck Oncology, v. 1, p. 27, 2009. Disponível em: https://doi.org/10.1186/1758-3284-1-27
Kitano, Shigeo. Development of Novel Gene-Modified T-Cell Therapies (CAR-T, TCR-T). Gan To Kagaku Ryoho, v. 50, n. 10, p. 1032-1037, 2023.
Li, Qiang; Tie, Yuan; Alu, Adrienne; Ma, Xin; Shi, Hong-Mei. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduction and Targeted Therapy, v. 8, n. 1, p. 31, 2023. Disponível em: https://doi.org/10.1038/s41392-022-01297-0
Liu, Yifei; Zhang, Ning; Wen, Yu; Wen, Jin. Câncer de cabeça e pescoço: patogênese e terapia direcionada. MedComm, v. 5, p. e702, 2024. Disponível em: https://doi.org/10.1002/mco2.702
Mody, Matthew D.; Rocco, James W.; Yom, Sue S.; Haddad, Robert I.; Saba, Nabil F. Head and neck cancer. The Lancet, v. 398, n. 10318, p. 2289-2299, 2021. Disponível em: https://doi.org/10.1016/S0140-6736(21)01550-6
Sanomachi, Tsutomu; Katsuya, Yuichi; Nakatsura, Tetsuya; Koyama, Takao. Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors. Cancers, v. 17, n. 12, p. 1945, 2025. Disponível em: https://doi.org/10.3390/cancers17121945
Sukrithan, Vedadren; Jain, Parul; Shah, Mihir Hrishikesh; Konda, Bhaskar. Kinase inhibitors in thyroid cancers. Endocrine Oncology, v. 3, n. 1, e220062, 2023. Disponível em: https://doi.org/10.1530/EO-22-0062
Sung, Yeji; Hong, Sung-Taek; Jang, Minjeong; Kim, Eun-Sook; Kim, Chan; Jung, Yuna; Youn, In-Chul; Chan Kwon, Ik; Cho, Seung-Wook; Ryu, Ji-Hoon. Predicting response to anti-EGFR antibody, cetuximab, therapy. Biomaterials, v. 303, p. 122382, 2023. Disponível em: https://doi.org/10.1016/j.biomaterials.2023.122382
Tang, Xiaoyu; Li, Rong; Wu, Dong; Wang, Yaqi; Zhao, Fang; Lv, Rui; Wen, Xia. Development and Validation of an ADME-Related Gene Signature… Frontiers in Immunology, v. 13, p. 905635, 2022. Disponível em: https://doi.org/10.3389/fimmu.2022.905635
Tahara, Makoto; Lim, Dong-Woo; Keam, Bhumsuk; Ma, Bo; Zhang, Li; Wang, Chu; Guo, Yan. Management approaches for recurrent or metastatic HNSCC after immunotherapy. Cancer Treatment Reviews, v. 136, p. 102938, 2025. Disponível em: https://doi.org/10.1016/j.ctrv.2025.102938
Vranic, Semir; Basu, Gunjan Deb; Hall, David William; Gatalica, Zoran. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group. Acta Medica Academica, v. 51, n. 3, p. 217-231, 2022. Disponível em: https://doi.org/10.5644/ama2006-124.392
Wachsmann, Tessa L. A.; Wouters, Anna K.; Remst, Daphne F. G.; Hagedoorn, Rianne S.; Meeuwsen, Marcel H.; Van Diest, Ewoud; Leusen, Jehoshua; Kuball, Jürgen; Falkenburg, Fred J. H.; Heemskerk, Mirjam H. M. Comparing CAR and TCR engineered T cell performance... OncoImmunology, v. 11, n. 1, 2033528, 2022. Disponível em: https://doi.org/10.1080/2162402X.2022.2033528
Xu, Yan; Gao, Zhen; Hu, Rui; Wang, Yue; Wang, Yu; Su, Zheng; Zhang, Xin; Yang, Jin; Mei, Ming; Ren, Ying; Li, Ming; Zhou, Xin. PD-L2 glycosylation promotes immune evasion… Journal for Immunotherapy of Cancer, v. 9, n. 10, e002699, 2021. Disponível em: https://doi.org/10.1136/jitc-2021-002699
Yang, Bi; Liu, Tao; Qu, Ying; Liu, Hongjun; Zheng, Sheng-Guo; Cheng, Bin; Sun, Jianjun.Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. Frontiers in Oncology, v. 8, p. 563, 2018. Disponível em: https://doi.org/10.3389/fonc.2018.00563
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
